News
Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy.
Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy, according to a study published online March 6 in Cureus. In a ...
In a groundbreaking discovery, scientists have found that the birth of new brain cells in adults plays a key role in verbal ...
Mike Frazier was living the dream. The 2013 graduate of Frederick County’s Millbrook High School moved to Seattle in 2022 ...
GlobalData on MSN18d
Neurona raises $102m to advance cell therapy for drug-resistant epilepsyNeurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for drug-resistant mesial temporal lobe epilepsy (MTLE). The ...
GlobalData on MSN1d
FDA grants breakthrough status to uniQure’s Huntington’s disease therapyThe US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...
In ‘The Mind Electric’ (Washington Square, June), the neurologist explores the roots of neurological disease and the ...
Researchers identified walking impairment and malarial disease sustained by Tutankhamun, supported by the discovery of canes ...
Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback